MétaCan
Menu
Back to cohort
Record W4399367382 · doi:10.1158/1078-0432.ccr-23-3552

Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma

2024· article· en· W4399367382 on OpenAlexafffund
Flurina A.M. Saner, Kazuaki Takahashi, Timothy Budden, Ahwan Pandey, Dinuka Ariyaratne, Tibor A. Zwimpfer, Nicola S. Meagher, Sián Fereday, Laura Twomey, Kathleen I. Pishas, Therese Hoang, Adelyn Bolithon, Nadia Traficante, Kathryn Alsop, Elizabeth L. Christie, Eun-Young Kang, Gregg Nelson, Prafull Ghatage, Cheng‐Han Lee, Marjorie J. Riggan, Jennifer Alsop, Matthias W. Beckmann, Jessica Boros, Alison H. Brand, Angela Brooks‐Wilson, Michael E. Carney, Penny Coulson, Madeleine Courtney‐Brooks, Kara L. Cushing‐Haugen, Cezary Cybulski, Mona El‐Bahrawy, Esther Elishaev, Ramona Erber, Simon A. Gayther, Aleksandra Gentry‐Maharaj, C. Blake Gilks, Paul R. Harnett, Holly R. Harris, Arndt Hartmann, Alexander Hein, Joy Hendley, Brenda Y. Hernandez, Anna Jakubowska, Mercedes Jimenez-Linan, Michael E. Jones, Scott H. Kaufmann, Catherine J. Kennedy, Tomasz Kluz, Jennifer M. Koziak, Björg Kristjansdottir, Nhu D. Le, Marcin Lener, Jenny Lester, Jan Lubiński, Constantina Mateoiu, Sandra Oršulić, Matthias Ruebner, Minouk J. Schoemaker, Mitul Shah, Raghwa Sharma, Mark E. Sherman, Yurii B. Shvetsov, T. Rinda Soong, Helen Steed, Paniti Sukumvanich, Aline Talhouk, Sarah E. Taylor, Robert A. Vierkant, Chen Wang, Martin Widschwendter, Lynne R. Wilkens, Stacey J. Winham, Michael S. Anglesio, Andrew Berchuck, James D. Brenton, Ian Campbell, Linda S. Cook, Jennifer A. Doherty, Peter A. Fasching, Renée T. Fortner, Marc T. Goodman, Jacek Gronwald, David G. Huntsman, Beth Y. Karlan, Linda E. Kelemen, Usha Menon, Francesmary Modugno, Paul D.P. Pharoah, Joellen M. Schildkraut, Karin Sundfeldt, Anthony J. Swerdlow, Ellen L. Goode, Anna DeFazio, Martin Köbel, Susan J. Ramus, David D.L. Bowtell, Dale W. Garsed

Bibliographic record

VenueClinical Cancer Research · 2024
Typearticle
Languageen
FieldMedicine
TopicOvarian cancer diagnosis and treatment
Canadian institutionsOccupational Cancer Research CentreVancouver General HospitalAlberta Health ServicesUniversity of British ColumbiaCanada's Michael Smith Genome Sciences CentreBC Cancer AgencyFoothills Medical CentreUniversity of AlbertaUniversity of Calgary
FundersHORIZON EUROPE European Research CouncilMedical Research CouncilNational Center for Advancing Translational SciencesNational Cancer InstituteU.S. Army Medical Research and Development CommandCancer Institute NSWCanadian Institutes of Health ResearchJanet D. Cottrelle FoundationKrebsliga SchweizMedical Research and Materiel CommandEisaiOvarian Cancer ActionAstraZenecaNational Health and Medical Research CouncilCancer Research UKSwedish Cancer FoundationBundesministerium für Bildung und ForschungMichael Smith Health Research BCGenentechVictorian Cancer AgencyClovis OncologyNational Institutes of HealthSchweizerischer Nationalfonds zur Förderung der Wissenschaftlichen ForschungU.S. Department of Defense
KeywordsOvarian carcinomaOvarian cancerBiologyCancer researchGermlineCD8TranscriptomeSerous carcinomaCancerImmunologyImmune systemGene expressionGeneticsGene

Abstract

fetched live from OpenAlex

PURPOSE: The purpose of this study was to evaluate RB1 expression and survival across ovarian carcinoma histotypes and how co-occurrence of BRCA1 or BRCA2 (BRCA) alterations and RB1 loss influences survival in tubo-ovarian high-grade serous carcinoma (HGSC). EXPERIMENTAL DESIGN: RB1 protein expression was classified by immunohistochemistry in ovarian carcinomas of 7,436 patients from the Ovarian Tumor Tissue Analysis consortium. We examined RB1 expression and germline BRCA status in a subset of 1,134 HGSC, and related genotype to overall survival (OS), tumor-infiltrating CD8+ lymphocytes, and transcriptomic subtypes. Using CRISPR-Cas9, we deleted RB1 in HGSC cells with and without BRCA1 alterations to model co-loss with treatment response. We performed whole-genome and transcriptome data analyses on 126 patients with primary HGSC to characterize tumors with concurrent BRCA deficiency and RB1 loss. RESULTS: RB1 loss was associated with longer OS in HGSC but with poorer prognosis in endometrioid ovarian carcinoma. Patients with HGSC harboring both RB1 loss and pathogenic germline BRCA variants had superior OS compared with patients with either alteration alone, and their median OS was three times longer than those without pathogenic BRCA variants and retained RB1 expression (9.3 vs. 3.1 years). Enhanced sensitivity to cisplatin and paclitaxel was seen in BRCA1-altered cells with RB1 knockout. Combined RB1 loss and BRCA deficiency correlated with transcriptional markers of enhanced IFN response, cell-cycle deregulation, and reduced epithelial-mesenchymal transition. CD8+ lymphocytes were most prevalent in BRCA-deficient HGSC with co-loss of RB1. CONCLUSIONS: Co-occurrence of RB1 loss and BRCA deficiency was associated with exceptionally long survival in patients with HGSC, potentially due to better treatment response and immune stimulation.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.003

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.143
GPT teacher head0.469
Teacher spread0.325 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations14
Published2024
Admission routes2
Has abstractyes

Explore more

Same venueClinical Cancer ResearchSame topicOvarian cancer diagnosis and treatmentFrench-language works237,207